Moreover, activation of GCN2 is not confined to EIF2AK inhibitors or RAFi; in the course of our work certain EGFR tyrosine kinase inhibitors including Erlotinib and Neratinib have also been shown to activate GCN2 in glioblastoma cell lines60. This evidence concerns the gene EIF2AK4 and glioblastoma.